Effect of Nafamostat on Postreperfusion Syndrome (PRS)

Seoul National University Hospital62 enrolled

Overview

This study intends to see the effect of nafamostat on the attenuation of postreperfusion syndrome (PRS) that frequently occurs during liver transplantation.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

TRIPLE

Enrollment

Conditions

Liver Transplantation Postreperfusion Syndrome

Interventions

NafamostatDRUG

0.2 mg/kg as bolus 1 minute before reperfusion

Normal salineDRUG

10 ml of normal saline

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * \>= 18 year old scheduled to undergo liver transplantation Exclusion Criteria: * Previous history of pulmonary, cardiovascular, or renal disease * Previous history of allergic reactions to nafamostat

Locations (1)

Seoul National University Hospital

Seoul, Seoul, South Korea

Outcomes

Primary Outcomes

Number of Participants With Moderate and Severe Postreperfusion Syndrome (PRS)

Before entering the study, we re-defined the criteria of PRS. From our clinical experiences, two types of PRS were observed according to its severity and treatment option. "Moderate" PRS was identical to previously defined PRS: more than 30% decrease of mean arterial pressure lasting over 1 min was observed within 5 min after reperfusion of the liver graft. However, we differentiated a "severe" form of PRS, in which MAP rapidly fell below 40 mmHg, from the moderate one, because severe PRS required prompt intervention to prevent a permanent damage of vital organs.

Time frame: during 5 min after reperfusion of liver graft

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.